|
|
| Name |
Bluestone, Jeffrey A. |
| Location
|
Sonoma BioTherapeutics |
| Primary Field
|
Immunology and Inflammation |
|
|
 Research Interests
|
|
Dr. Bluestone is an academic leader on a national and international scale. He was founding the director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy. Dr. Bluestone also served as Executive Vice Chancellor and Provost at UCSF and was founding Director and CEO of the Parker Institute for Cancer Immunotherapy. Over the past four decades, he has published over 500 papers focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His work has informed the development of multiple immunotherapies, including the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation; the FDA-approved, anti-human CD3 antibody, Teplizumab, the first immunotherapy to treat Type 1 Diabetes; and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma. His recent research has focused on the critical role of regulatory T cells in autoimmune diseases, which is being exploited as a cell-based therapy to treat autoimmune diseases and organ transplant rejection. Importantly, Jeff have trained more than 100 students, post-docs and fellows, who have gone onto have outstanding careers in both academia and industry. |
|
|
|